Cargando…
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
BACKGROUND: Limited therapeutic options exist for coronavirus disease 2019 (COVID-19). COVID-19 convalescent plasma (CCP) is a potential therapeutic, but there is limited data for patients with moderate-to-severe disease. RESEARCH QUESTION: What are outcomes associated with administration of CCP in...
Autores principales: | Briggs, Neima, Gormally, Michael V., Li, Fangyong, Browning, Sabrina L., Treggiari, Miriam M., Morrison, Alyssa, Laurent-Rolle, Maudry, Deng, Yanhong, Hendrickson, Jeanne E., Tormey, Christopher A., Desruisseaux, Mahalia S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318280/ https://www.ncbi.nlm.nih.gov/pubmed/34320004 http://dx.doi.org/10.1371/journal.pone.0254453 |
Ejemplares similares
-
Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience
por: Browning, Sabrina L., et al.
Publicado: (2020) -
Introduction to the special issue on interferon responses: From cells to systems
por: Morrison, Juliet, et al.
Publicado: (2022) -
COVID-19 and the Coombs test
por: Hendrickson, Jeanne E., et al.
Publicado: (2020) -
Earlier the better: convalescent plasma
por: Tobian, Aaron A.R., et al.
Publicado: (2020) -
Late Treatment for COVID-19 With Convalescent Plasma
por: Senefeld, Jonathon W., et al.
Publicado: (2022)